The Division of Atherosclerosis and Vascular Medicine has two main centers where the bulk of our clinical research, which focuses on multiple aspects of the metabolic syndrome including lipid disorders, obesity, type 2 diabetes mellitus, and cardiovascular disease, is conducted.
Research at the Behavioral Medicine Research Center, which is directed by John P. Foreyt, Ph.D., focuses on weight reduction through behavior modification and the use of anti-obesity drugs. The BMRC is a participant in a large 12-year multi-center clinical trial of the effects of weight reduction on cardiovascular mortality in obese, diabetic patients. In addition, the BMRC develops weight loss programs for high risk populations, particularly Mexican- and African-Americans.
The Center for Cardiovascular Disease Prevention is directed by Christie M. Ballantyne, M.D., and is the site of many clinical investigations within the section. The CCDP conducts numerous clinical trials of lipid-lowering drugs and collaborates with basic research studies of lipid-modifying activities in normal and hyperlipidemic plasma. Major efforts in clinical research incorporate state-of-the-art methods, most notably stable isotope studies of human metabolism and magnetic resonance imaging studies of atherogenesis and its regression following various therapies.